For a software-as-a-medical-device (SaMD) product with annual software updates, determining what constitutes a significant change requiring new PMCF evaluation adds regulatory complexity to the product development cycle
Although inexpensive and easy to carry out, this method is only able to detect cases with 20% or less of mean normal G6PD activity and misses most of the moderate G6PD activity especially in female heterozygotes ( Quantitative Glucose-6-Phosphate Dehydrogenase Activity Several quantitative test kits have been introduced in recent years which are superior to the FST in terms of accuracy and sensitivity
Two versions circulate: one developed primarily for pigmentation, and a second, broader-acting analog that also affects sexual arousal pathways
This is particularly valuable for teams in health economics and outcomes research (HEOR), epidemiology, and pharmacovigilance who are tasked with evaluating real-world performance
I like that theres usually a clear reason behind your perspective, not just a reaction to the latest headline
